Pathology: mUC - L1 - all population; mUC - L2 - all population; mUC - L2 - PDL1 positive;
mUC - L1 - all population | mUC - L2 - all population | mUC - L2 - PDL1 positive | |||
KEYNOTE-361 (P vs C), 2021 | KEYNOTE-361 (PC vs C), 2021 | KEYNOTE-045 (all population), 2017 | KEYNOTE-045 (PDL1 CPS >10%), 2017 | ||
pembrolizumab alone | 3 | T1 | T1 | T1 | |
pembrolizumab plus SoC | 1 | T1 | |||
gemcitabine plus platin | 0 | T0 | |||
Standard of Care (SoC) | 0 | T0 | T0 | T0 |